Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
Free Radical Research|March 17, 2007
Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscleDamian M Bailey, Leslie Lawrenson, Jane McEneny, et al.
Diabetes Care|September 27, 2012
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetesSunder Mudaliar, Debra A Armstrong, Annie A Mavian, et al.
Diabetes Care|March 5, 2002
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetesNeelima V Chu, Alice P S Kong, Dennis D Kim, et al.
Diabetologia|October 17, 2018
Correction to: Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistanceLaura Formentini, Alexander J Ryan, Manuel Gálvez-Santisteban, et al.
Clinical Science (London, England : 1979)|May 7, 2013
Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoaPam R Taub, Israel Ramirez-Sanchez, Theodore P Ciaraldi, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
Diabetologia|August 4, 2017
Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistanceLaura Formentini, Alexander J Ryan, Manuel Gálvez-Santisteban, et al.
Gastroenterology|June 4, 2013
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver diseaseSunder Mudaliar, Robert R Henry, Arun J Sanyal, et al.
The Journal of Biological Chemistry|June 3, 2017
Deletion of interleukin 1 receptor-associated kinase 1 (Irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscleXiao-Jian Sun, Soohyun Park Kim, Dongming Zhang, et al.
European Heart Journal|July 28, 2016
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studiesHelen M Colhoun, Henry N Ginsberg, Jennifer G Robinson, et al.
Pageof 15